A Multicenter Registry Study Assessing Patient Reported Outcome, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Vunakizumab (Primary)
- Indications Ankylosing spondylitis; Arthritis; Axial spondyloarthritis; Behcet's syndrome; Giant cell arteritis; Juvenile rheumatoid arthritis; Polymyalgia rheumatica; Psoriatic arthritis; Takayasu syndrome
- Focus Therapeutic Use
- Acronyms V-MIRACLE
- 16 Jan 2025 New trial record